Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Agenus (Details)

v3.21.2
Royalty Purchase Agreements - Agenus (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Nov. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Agreements              
Payments to acquire milestones and royalties         $ 13,500    
Long-term royalty receivables     $ 48,075   48,075   $ 34,575
Revenue from contracts with customers     $ 525 $ 53 544 $ 553  
Impairment of long-term royalty receivable         0   $ 0
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus              
Agreements              
Amount of milestone achieved   $ 10,000          
Agenus | Royalty Purchase Agreement              
Agreements              
Payments to acquire milestones and royalties $ 15,000            
Long-term royalty receivables 15,000            
Impairment of long-term royalty receivable         $ 0    
Agenus | Royalty Purchase Agreement | Silicon Valley Bank Loans              
Agreements              
Proceeds from issuance of long-term debt $ 7,500            
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets              
Agreements              
Royalties entity has right to receive (as a percent) 33.00%            
Number of licensed products related to milestone and royalties | product 6            
Purchased percentage of milestones 10.00%            
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product              
Agreements              
Royalties entity has right to receive (as a percent) 33.00%            
Purchased percentage of milestones 10.00%            
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500            
Amount of milestone achieved   1,000          
Cash receipts for achievement of contractual milestones   $ 1,000